Capstone Investment Advisors
SRPT icon

Capstone Investment Advisors’s Sarepta Therapeutics SRPT Stock Holding History

Capstone Investment Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-6,000
Closed -$452K – 1451
2019
Q3 		$452K Buy
+6,000
New +$709K ﹤0.01% 1112

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Capstone Investment Advisors's SRPT Position: Q4 2025 in Review

Capstone Investment Advisors sold out of Sarepta Therapeutics (SRPT) in Q4 2025, closing a stake of 30,000 shares — an estimated $578K sold.

Capstone Investment Advisors first reported a position in SRPT in Q2 2013 and held it in 4 quarters. The position peaked at $1.27M in Q1 2025. 344 funds tracked by Wall St. Rank hold SRPT as of Q4 2025.

  • Capstone Investment Advisors reported no remaining Sarepta Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Capstone Investment Advisors sold 30,000 Sarepta Therapeutics shares in Q4 2025, an estimated $578K.
  • Capstone Investment Advisors first reported a position in Sarepta Therapeutics in Q2 2013 and held it in 4 quarters.
  • Capstone Investment Advisors's Sarepta Therapeutics position peaked at $1.27M in Q1 2025.
  • 344 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2025.

Based on Capstone Investment Advisors's 13F filing for Q4 2025, filed 17 Feb 2026.